IDEXX LABORATORIES INC /DE (IDXX) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 150.00M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 299.87M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 3.44B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $150.00M | $299.87M | (m) | (m) | $3.44B | (m) |
| 2026-03-31 | (m) | (m) | $150.00M | $299.85M | (m) | (m) | $3.39B | (m) |
| 2025-12-31 | (m) | (m) | $75.00M | $374.84M | (m) | (m) | $3.35B | (m) |
| 2025-09-30 | (m) | (m) | $150.00M | $374.82M | (m) | (m) | $3.39B | (m) |
| 2025-06-30 | (m) | (m) | $74.99M | $449.81M | (m) | (m) | $3.33B | (m) |
| 2025-03-31 | (m) | (m) | $170.93M | $449.80M | (m) | (m) | $3.21B | (m) |
| 2024-12-31 | (m) | (m) | $167.79M | $449.79M | (m) | (m) | $3.29B | (m) |
| 2024-09-30 | (m) | (m) | $99.14M | $524.76M | (m) | (m) | $3.35B | (m) |
| 2024-06-30 | (m) | (m) | $170.11M | $524.74M | (m) | (m) | $3.41B | (m) |
| 2024-03-31 | (m) | (m) | $75.00M | $620.78M | (m) | (m) | $3.35B | (m) |
| 2023-12-31 | (m) | (m) | $75.00M | $622.88M | (m) | (m) | $3.26B | (m) |
| 2023-09-30 | (m) | (m) | $149.99M | $618.81M | (m) | (m) | $3.09B | (m) |
| 2023-06-30 | (m) | (m) | $74.99M | $696.84M | (m) | (m) | $2.87B | (m) |
| 2023-03-31 | (m) | (m) | $74.99M | $696.36M | (m) | (m) | $2.81B | (m) |
| 2022-12-31 | (m) | (m) | $74.98M | $694.39M | (m) | (m) | $2.75B | (m) |
| 2022-09-30 | (m) | (m) | $0.00 | $760.81M | (m) | (m) | $2.64B | (m) |
| 2022-06-30 | (m) | (m) | $0.00 | $768.00M | (m) | (m) | $2.61B | (m) |
| 2022-03-31 | (m) | (m) | $0.00 | $773.38M | (m) | (m) | $2.59B | (m) |
| 2021-12-31 | (m) | (m) | $75.00M | $775.21M | (m) | (m) | $2.44B | (m) |
| 2021-09-30 | (m) | (m) | $74.99M | $778.02M | (m) | (m) | $2.39B | (m) |
| 2021-06-30 | (m) | (m) | $124.98M | $780.08M | (m) | (m) | $2.41B | (m) |
| 2021-03-31 | (m) | (m) | $124.97M | $778.75M | (m) | (m) | $2.33B | (m) |
| 2020-12-31 | (m) | (m) | $49.99M | $858.49M | (m) | (m) | $2.29B | (m) |
| 2020-09-30 | (m) | (m) | $49.98M | $853.32M | (m) | (m) | $2.05B | (m) |
| 2019-12-31 | (m) | (m) | $0.00 | $698.91M | (m) | (m) | $1.83B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |